Development and clinical evaluation of a nanoemulsion for buccal delivery of cannabis extract in refractory chronic pain
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2026.115162 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Alessandra Spirito und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Napoli, Italy. Hauptthemen laut MEDLINE: Plant Extracts, Chronic Pain, Cannabis, Dronabinol. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Campania Luigi Vanvitelli.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Cannabinoid-based therapies have gained increasing attention for the management of chronic and treatment-resistant pain, although their clinical application is limited by the poor aqueous solubility and variable bioavailability of Δ9-tetrahydrocannabinol (THC). In this study, we developed and characterized a nanoemulsion (THC-NE) for buccal administration of a Cannabis sativa L. extract (Bedrocan®), with the aim of improving solubility, stability and bioavailability. The optimized formulation, composed of pharmaceutically acceptable excipients, showed a narrow droplet size distribution (DH ≈ 73 nm, PDI ≈ 0.2), a THC content consistent with the theoretical value (3.53 ± 0.56 mg/mL), and good physicochemical stability at 4°C for at least 90 days. The formulation exhibited favorable mucoadhesive properties and enhanced THC permeation across the mucosa compared with the oil extract while maintaining its properties upon extensive dilution in simulated buccal fluids and after spray nebulization, supporting its suitability for oromucosal delivery. In vitro release studies confirmed sustained THC release from THC-NE, whereas negligible release was observed from the oil extract, highlighting the role of nanoformulation in enhancing solubilization and controlled release. An observational study was conducted in 18 patients with chronic pain unresponsive to standard treatments. After a median follow-up of 189 days, mean pain scores (NRS) decreased significantly from 8.6 ± 0.9 to 5.4 ± 2.8 (p < 0.001), with 83% of patients achieving a ≥ 20% reduction. Among responders, the mean NRS decreased by 45% and treatment persistence was found to be high, with 64% of patients still remaining under therapy after six months. A total of 17 adverse events were reported in 11 patients, most of which were mild to moderate and transient. Additionally, treatment interruption occurred in three patients due to adverse events, in other three owing to limited efficacy and in two for logistical reasons. Overall, these findings indicate that buccal administration of THC-NE represents a promising patient-friendly approach for cannabis-based therapy, offering improved solubility, controlled release and meaningful clinical benefit in patients with refractory chronic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Napoli, Italy.
- Department of Chemical, Materials and Industrial Production Engineering-DICMAPI, University of Naples Federico II, P.le Tecchio 80, 80125 Naples, Italy.
- Farmacia Caputo, Nocera Superiore, SA, Italy.
- Istituto Nazionale Tumori di Napoli - IRCCS "G. Pascale", Naples, Italy.
- Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Napoli, Italy.
- DiSTABiF, University of Campania "Luigi Vanvitelli", Via A. Vivaldi, 43, 81100 Caserta, Italy. Electronic address: ivana.dangelo@unicampania.it.
Förderung
- University of Campania Luigi Vanvitelli
Zitieren
APA
Spirito, A., Provenzano, R., Vitiello, A., Di Spirito, N. A., Izzo, L., Lombardi, A., Maiolino, P., Pane, C., Ungaro, F., Saccà, F., d'Angelo, I., & Miro, A. (2026). Development and clinical evaluation of a nanoemulsion for buccal delivery of cannabis extract in refractory chronic pain. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115162
Vancouver
Spirito A, Provenzano R, Vitiello A, Di Spirito NA, Izzo L, Lombardi A, et al. Development and clinical evaluation of a nanoemulsion for buccal delivery of cannabis extract in refractory chronic pain. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115162
BibTeX
@article{Spirito2026,
author = {Spirito, Alessandra and Provenzano, Romina and Vitiello, Antonella and Di Spirito, Nicola Antonio and Izzo, Luana and Lombardi, Annunziata and Maiolino, Piera and Pane, Chiara and Ungaro, Francesca and Saccà, Francesco and d'Angelo, Ivana and Miro, Agnese},
title = {Development and clinical evaluation of a nanoemulsion for buccal delivery of cannabis extract in refractory chronic pain},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2026.115162}
}
EUVIMED